Edwin Ofori Atta: High-Dose Vitamin C and Vascular Function
Edwin Ofori Atta, Head Of Pharmacy at Kumasi Hospital, shared a post on LinkedIn:
“Taking 2 g of vitamin C reduces arterial stiffness by about 9.6 percent within 6 hours and reduces platelet aggregation by about 35%, which may help lower the risk of blood clots.
Specifically high-dose vitamin C reducing arterial stiffness and platelet aggregation within 6 hours, are supported by clinical studies on cardiovascular health.
Vitamin C functions as a powerful antioxidant, scavenging free radicals and improving the bioavailability of nitric oxide.
Increased nitric oxide bioavailability allows blood vessels to relax (vasodilation) and prevents platelets from sticking together.
Double-blind, randomized study found that acute oral administration of high-dose vitamin C significantly increased plasma levels, which reduced the augmentation index (a key measure of arterial stiffness) within 6 hours.
While this study was on healthy individuals, similar studies indicate that vitamin C provides significant cardiovascular benefits by protecting the endothelium (vessel lining) and reducing platelet activation, particularly in individuals with high oxidative stress.”
Stay updated with Hemostasis Today.
-
May 24, 2026, 13:10Thomas Pincez: Emerging Challenges in Sickle Cell Disease Gene Therapy and Cancer Risk
-
May 24, 2026, 12:04Kalpana Gupta Shekhawat: Ferritin Is More Than an Iron Marker
-
May 24, 2026, 11:50Peter Zdziarski: Making Rare Disease Research More Human
-
May 24, 2026, 11:39Bram Berkelmans: Donating with a View
-
May 24, 2026, 11:28Ratiporn Chinthammit: A Meaningful Exchange in aHUS and PNH Education
-
May 24, 2026, 11:17Mary Ann Sromoski: Transfusion Medicine and Patient Blood Management in Practice
-
May 24, 2026, 07:45Thierry Burnouf: Advances in Platelet Membrane-Coated Nanoparticles for Targeted Therapeutics and Regenerative Medicine
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management